Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Atara Biotherapeutics (ATRA) Research & Development (2022 - 2026)

Atara Biotherapeutics filings provide 5 years of Research & Development readings, the most recent being $164000.0 for Q1 2026.

  • On a quarterly basis, Research & Development fell 99.4% to $164000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $10.2 million, a 92.37% decrease, with the full-year FY2025 number at $37.4 million, down 75.28% from a year prior.
  • Research & Development hit $164000.0 in Q1 2026 for Atara Biotherapeutics, up from -$223000.0 in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $75.0 million in Q1 2022 to a low of -$223000.0 in Q4 2025.
  • Median Research & Development over the past 5 years was $45.5 million (2024), compared with a mean of $40.4 million.
  • Biggest five-year swings in Research & Development: decreased 13.49% in 2023 and later tumbled 100.78% in 2025.
  • Atara Biotherapeutics' Research & Development stood at $62.5 million in 2022, then fell by 20.66% to $49.6 million in 2023, then tumbled by 42.09% to $28.7 million in 2024, then tumbled by 100.78% to -$223000.0 in 2025, then skyrocketed by 173.54% to $164000.0 in 2026.
  • The last three reported values for Research & Development were $164000.0 (Q1 2026), -$223000.0 (Q4 2025), and $2.9 million (Q3 2025) per Business Quant data.